【摘要】：目的篩選轉(zhuǎn)化生長(zhǎng)因子(TGF-β)信號(hào)通路Ⅰ型受體抑制劑,并探討活性化合物的結(jié)構(gòu)特征。方法利用SMAD3熒光素酶報(bào)告系統(tǒng)對(duì)靶向TGF-β信號(hào)通路Ⅰ型受體激活素受體樣激酶(ALK)設(shè)計(jì)合成的170個(gè)化合物進(jìn)行活性初篩;通過(guò)分子水平激酶活性分析評(píng)價(jià)初篩活性化合物對(duì)ALK4、ALK5或ALK7激酶的選擇性抑制活性;采用EGFP-SMAD2熒光蛋白轉(zhuǎn)核模型,對(duì)篩選結(jié)果進(jìn)行確證;參照SB431542與ALK5分子對(duì)接情況,對(duì)活性化合物進(jìn)行構(gòu)效關(guān)系的分析。結(jié)果初篩發(fā)現(xiàn)15個(gè)化合物對(duì)TGF-β引起的SMAD3熒光素酶報(bào)告基因表達(dá)達(dá)到≥25%的抑制程度;在分子水平對(duì)ALK4、ALK5或ALK7也具有抑制活性,并表現(xiàn)出一定的選擇性。其中,化合物63對(duì)ALK4和ALK7的IC50值分別為0.234和0.370μmol/L,對(duì)ALK5選擇性較差,化合物64對(duì)ALK4、ALK5和ALK7的IC50值分別為10、6和85 nmol/L。這兩個(gè)化合物在TGF-β1誘導(dǎo)EGFP-SMAD2核轉(zhuǎn)位中同樣表現(xiàn)出濃度依賴(lài)性抑制活性,IC50值分別為0.45和6.30μmol/L。MTT細(xì)胞增殖抑制實(shí)驗(yàn)表明,63和64在有效濃度下均無(wú)細(xì)胞毒性。構(gòu)效關(guān)系分析表明,1,2,4-三芳基-1H-咪唑母核、1,3,5-三芳基-1H-吡唑母核、3,4-亞甲二氧基苯基、6-甲基-吡啶-2基和4-氨基羧基取代基團(tuán)的化合物預(yù)計(jì)具有更好的活性。結(jié)論篩選得到2個(gè)與陽(yáng)性化合物SB431542活性相當(dāng)?shù)腡GF-β信號(hào)通路Ⅰ型受體抑制劑,其中63對(duì)ALK4和ALK7具有選擇性,64對(duì)ALK4、ALK5和ALK7均有抑制活性。
[Abstract]:Objective to screen type I receptor inhibitors of transforming growth factor (TGF- 尾) signaling pathway and to investigate the structural characteristics of active compounds. Methods using SMAD3 luciferase reporting system, 170 compounds designed and synthesized by type I receptor activator receptor-like kinase (ALK) targeting TGF- 尾 signaling pathway were screened. The selective inhibitory activity of active compounds against ALK4,ALK5 or ALK7 kinase was evaluated by molecular level kinase activity analysis. The screening results were confirmed by EGFP-SMAD2 fluorescent protein transnucleation model. The structure-activity relationship of active compounds was analyzed. Results it was found that 15 compounds could inhibit the expression of SMAD3 luciferase reporter gene induced by TGF- 尾 by more than 25%, and also had inhibitory activity on ALK4,ALK5 or ALK7 at molecular level, and showed certain selectivity. The IC50 values of compound 63 to ALK4 and ALK7 were 0.234 and 0.370 渭 mol/L, respectively, and the IC50 values of compound 64 to ALK4,ALK5 and ALK7 to ALK5 were 10 6 and 85 nmol/L., respectively. The two compounds also showed concentration-dependent inhibitory activity in TGF- 尾 1-induced EGFP-SMAD2 nuclear translocation. The IC50 values were 0.45 and 6.30 渭 mol/L.MTT, respectively. The results showed that 63 and 64 had no cytotoxicity at the effective concentration. The results of structure-activity relationship analysis showed that the compounds of 1o 2n 4- triaryl-1H imidazole mother nucleus, 1o 3H aryl 1 H pyrazole parent nucleus, 3o 4 methylene dioxy phenyl, 6 methyl pyridyl 2 group and 4 amino carboxyl substituent group were expected to have better activity. Conclusion two type I receptor inhibitors of TGF- 尾 signaling pathway were obtained which were comparable to the SB431542 activity of the positive compounds. 63 of them were selective to ALK4 and ALK7, and 64 to ALK4,ALK5 and ALK7.
【作者單位】： 軍事醫(yī)學(xué)科學(xué)院毒物藥物研究所 抗毒藥物與毒理學(xué)國(guó)家重點(diǎn)實(shí)驗(yàn)室;北京師范大學(xué)生命科學(xué)學(xué)院;
【基金】：國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目資助(81430090) 國(guó)家“重大新藥創(chuàng)制”科技重大專(zhuān)項(xiàng)資助項(xiàng)目(2012ZX09301003-003;2009ZX09501031)
【分類(lèi)號(hào)】：R91

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 劉浩;魏偉;;TGFβ信號(hào)轉(zhuǎn)導(dǎo)通路及以其為靶點(diǎn)的肝纖維化治療[J];中國(guó)藥理學(xué)通報(bào);2007年05期

2 代現(xiàn)平;李行舟;鄭志兵;李松;;1,5-二取代吡唑-3-甲酰胺類(lèi)新化合物的合成及其生物活性[J];中國(guó)藥物化學(xué)雜志;2006年06期

3 李行舟;劉豐年;代現(xiàn)平;李松;;轉(zhuǎn)化生長(zhǎng)因子β信號(hào)及其信號(hào)通路阻斷劑的研究進(jìn)展[J];國(guó)外醫(yī)學(xué).藥學(xué)分冊(cè);2006年05期

4 楊人強(qiáng);轉(zhuǎn)化生長(zhǎng)因子β家族信號(hào)轉(zhuǎn)導(dǎo)的研究進(jìn)展[J];江西醫(yī)學(xué)院學(xué)報(bào);2004年01期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 龍隆;李菲菲;李行舟;陳偉;李微;王莉莉;;轉(zhuǎn)化生長(zhǎng)因子βⅠ型受體抑制劑的體外篩選及構(gòu)效關(guān)系分析[J];國(guó)際藥學(xué)研究雜志;2017年06期

2 艾思羽;任艷玲;張?zhí)黻?秦臻;;補(bǔ)腎方藥防治絕經(jīng)后骨質(zhì)疏松癥TGF-β1/Smads信號(hào)轉(zhuǎn)導(dǎo)通路的研究進(jìn)展[J];河北中醫(yī);2017年02期

3 常香榮;劉蓓蕾;張海云;;miR-520通過(guò)靶向調(diào)節(jié)BAMBI抑制肝星狀細(xì)胞增殖的研究[J];現(xiàn)代醫(yī)學(xué);2016年11期

4 胡彥武;劉凱;閆夢(mèng)彤;王雷;劉明冬;于俊林;武子敬;;五味子藤莖提取物抗大鼠肝纖維化作用及機(jī)制探討[J];中國(guó)實(shí)驗(yàn)方劑學(xué)雜志;2016年17期

5 零偉德;杜剛;;柿葉黃酮對(duì)糖尿病腎病大鼠血糖值及腎組織中TGF-β_1和MMP-9的影響[J];中國(guó)實(shí)驗(yàn)方劑學(xué)雜志;2016年16期

6 陳建清;林穗金;鄭妮;;桑葉多糖對(duì)糖尿病小鼠腎病的影響[J];中國(guó)醫(yī)院藥學(xué)雜志;2016年10期

7 諶凌燕;林卓殷;陳鵬;陳禎;陳小婷;許偉丹;;犀角地黃湯對(duì)小兒過(guò)敏性紫癜免疫機(jī)制的影響[J];按摩與康復(fù)醫(yī)學(xué);2015年22期

8 江宇峰;伍超;吳佳俊;王極宇;馬成驍;陳帆;吳德衛(wèi);楊明;鄭凌云;楊雁;;MAPK抑制因子對(duì)HSC中Smad2/3磷酸化及Smad4核轉(zhuǎn)位的影響[J];安徽醫(yī)科大學(xué)學(xué)報(bào);2015年09期

9 景晶;趙金英;華冰;薛e，

本文編號(hào)：2288626